Zoledronic acid + Estramustine + Docetaxel
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone-Refractory Prostate Cancer
Conditions
Hormone-Refractory Prostate Cancer
Trial Timeline
Apr 1, 2002 → Sep 1, 2007
NCT ID
NCT00151073About Zoledronic acid + Estramustine + Docetaxel
Zoledronic acid + Estramustine + Docetaxel is a phase 2 stage product being developed by Novartis for Hormone-Refractory Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00151073. Target conditions include Hormone-Refractory Prostate Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Hormone-Refractory Prostate Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00151073 | Phase 2 | Completed |
Competing Products
8 competing products in Hormone-Refractory Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzalutamide | Astellas Pharma | Phase 2 | 35 |
| YM598 | Astellas Pharma | Phase 2 | 27 |
| amg 162 | Amgen | Phase 3 | 40 |
| Denosumab | Amgen | Phase 3 | 40 |
| IV Bisphosphonate q 4 weeks | Amgen | Phase 2 | 35 |
| Dasatinib | Bristol Myers Squibb | Phase 2 | 35 |
| ILX651 | Sanofi | Phase 2 | 35 |
| VIR-5500 | Vir Biotechnology | Phase 1 | 30 |